To our knowledge, only four studies have explored the specific association between these recommendations and BC risk [12–15] and none of them has classified the cases by tumor subtype considering hormonal receptors and the Human Epidermal Growth Factor Receptor 2 (HER2) status. This evidence concerns the gene ERBB2 and neoplasm.